Comparative cardiovascular and renal effectiveness and safety of Empagliflozin and other SGLT2i in patients with type 2 diabetes (T2D), with and without baseline kidney disease in the United States

ENCePP Code of conduct

No

Data sources

• Data source(s), other:
  PCORnet United States
• Data sources (types):
  Electronic healthcare records (EHR)

  Other
• Data sources (types), other:
  This study will utilize several types of data from inpatient and outpatient healthcare encounters from electronic medical records from approximately 20 health systems in the US with data mapped to the PCORnet Common Data Model. Data types will include renal laboratory data, prescription data, and relevant medical diagnoses.

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No